Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2012 Dec 13;120(25):4906-8. doi: 10.1182/blood-2012-09-452755.

MDS: unraveling the mystery.

Author information

1
Duke Cancer Institute.

Abstract

In this issue of Blood, Sekeres et al report a phase 2 study of lenalidomide and azacitidine for higher risk myelodysplastic syndromes (MDS). High overall response and duration of response supports the concept of combination, multitargeted approaches rather than traditional chemotherapeutics for this disease.

PMID:
23243154
DOI:
10.1182/blood-2012-09-452755
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center